Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration

Background Our aim was to evaluate the short-term safety and efficacy of combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in neovascular age-related macular degeneration (AMD). Methods A prospective non-randomized interventional case series of 30 eyes of 30 patients...

Full description

Saved in:
Bibliographic Details
Published in:Graefe's archive for clinical and experimental ophthalmology 2008-01, Vol.246 (1), p.17-25
Main Authors: Ladewig, Markus S., Karl, Stefanie E., Hamelmann, Victoria, Helb, Hans-Martin, Scholl, Hendrik P. N., Holz, Frank G., Eter, Nicole
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Choroidal Neovascularization - drug therapy
Choroidal Neovascularization - etiology
Choroidal Neovascularization - physiopathology
Clinical Investigation
Combined Modality Therapy
Female
Fluorescein Angiography
Humans
Injections
Macular degeneration
Macular Degeneration - complications
Macular Degeneration - drug therapy
Macular Degeneration - physiopathology
Male
Medicine
Medicine & Public Health
Ophthalmology
Photochemotherapy
Photosensitizing Agents - therapeutic use
Porphyrins - therapeutic use
Prospective Studies
Retina - pathology
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity - physiology
Vitreous Body
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Our aim was to evaluate the short-term safety and efficacy of combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in neovascular age-related macular degeneration (AMD). Methods A prospective non-randomized interventional case series of 30 eyes of 30 patients with choroidal neovascularization (CNV) caused by AMD was studied. All patients were treated with PDT followed by an intravitreal injection of bevacizumab (1.5 mg) on the same day. Ophthalmic evaluations included determination of best-corrected visual acuity by using ETDRS charts. CNV lesion characteristics were determined by fluorescein angiography, and retinal morphology by optical coherence tomography. Review examinations were performed 1, 4, and 12 weeks following treatment. Results The median ETDRS letter scores increased by 3 letters after 4 weeks and 4.3 letters after 12 weeks. Median central retinal thickness decreased from the baseline by 145 μm (week 1), 205 μm (week 4), and 171 μm (week 12), respectively ( P  
ISSN:0721-832X
1435-702X
DOI:10.1007/s00417-007-0654-x